profit from every $100 of sales.
$0$100
Medpace Holdings
$653.94-0.44% today
+10.6% in 1 year
1-year low $393.421-year high $692.68
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
You pay $40.55 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Medpace Holdings sold, what it kept, and what it did with the cash.
Sales went from $1.46 billion in 2022 to $2.53 billion in 2025, with $451 million of profit last year.
SalesProfit
Medpace Holdings handed back more cash to shareholders than it generated last year.
Buybacks $917M
Free cash flow 2025$682M
Bought back its own shares$917M
Paid as dividends–
Cash vs. debt$497M vs. $114M
Medpace Holdings vs. similar companies
Medpace Holdings grows in the middle of these 5 and is the most expensive for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Medpace Holdings | 40.5× · Expensive | ||
 Illumina | 36.8× · Expensive | ||
 Labcorp Holdings | 34.3× · Expensive | ||
 Quest Diagnostics | 28.8× · Fair price | ||
 Guardant Health | No profit yet |
AI analysis
An AI analyst reads Medpace Holdings's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 926 | 1,142 | 1,460 | 1,886 | 2,109 | 2,530 | |
| – | – | 432 | 525 | 656 | 761 | |
| 167 | 199 | 279 | 337 | 447 | 535 | |
| 187 | 220 | 301 | 363 | 476 | 563 | |
| 145 | 182 | 245 | 283 | 404 | 451 | |
| 3.84 | 4.81 | 7.28 | 8.88 | 12.63 | 15.28 | |
| – | – | 29.6% | 27.8% | 31.1% | 30.1% | |
| 18.0% | 17.4% | 19.1% | 17.9% | 21.2% | 21.1% | |
| 15.7% | 15.9% | 16.8% | 15.0% | 19.2% | 17.8% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 1,391 | 1,660 | 1,352 | 1,657 | 2,101 | 1,975 |
| Cash | 278 | 461 | 28 | 245 | 669 | 497 |
| Total debt | – | – | 189 | 142 | 126 | 114 |
| Total liabilities | 585 | 707 | 966 | 1,098 | 1,275 | 1,516 |
| 806 | 953 | 386 | 559 | 826 | 459 | |
| 38 | 38 | 34 | 32 | 32 | 30 | |
| 16.4% | 16.5% | 38.3% | 38.0% | 37.1% | 73.8% | |
| 18.0% | 19.1% | 63.5% | 50.6% | 49.0% | 98.3% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 259 | 263 | 388 | 433 | 609 | 713 | |
| 31 | 28 | 37 | 37 | 37 | 31 | |
| 227 | 235 | 351 | 397 | 572 | 682 | |
| Dividends paid | – | – | – | – | – | – |
| 98 | 62 | 848 | 144 | 170 | 917 | |
| 14 | 14 | 21 | 21 | 26 | 35 |
Valuation
- 40.5×
- 38.5×
- 1.27
- 19.7×
- 7.2×
- 26.8×
- 31.8×
- 3.7%
- 2.5%
- 0.0%
Profitability
- 30.1%
- 21.1%
- 17.8%
- 21.7%
- 56.1%
- 41.0%
- 120.9%
- 21.6%
- 71.7%
- –
Growth
- +22.3%
- +31.8%
- +19.2%
- –
- −5.3%
Financial health
- -0.9×
- 0.24
- 6.9%
- –
- 0.85
- 0.85
- 1.26
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 1%of 952
Top 20%of 884
Bottom 30%of 601
Top 25%of 886
Top 30%of 987
What analysts expect
- Average price target
- $498.86
- Range
- $400.00 – $582.00
- 10 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 22, 2026 | 4.28 | 3.74 | +14.4% |
| Feb 9, 2026 | 4.67 | 4.19 | +11.5% |
| Oct 22, 2025 | 3.86 | 3.53 | +9.3% |
| Jul 21, 2025 | 3.10 | 2.98 | +4.0% |
| Apr 21, 2025 | 3.67 | 3.06 | +19.9% |
| Feb 10, 2025 | 3.67 | 2.96 | +24.0% |
| Oct 21, 2024 | 3.01 | 2.78 | +8.3% |
| Jul 22, 2024 | 2.75 | 2.54 | +8.3% |
News
Medpace raises 2026 EPS guidance rangeSeeking Alpha · Oct 21, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
5/7Passes 5 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
62Pass
Benjamin Graham
36No pass
Philip Fisher
80Pass
Peter Lynch
90Pass
Joel Greenblatt
47No pass
Charlie Munger
81Pass
Terry Smith
81Pass
Questions about Medpace Holdings
Is Medpace Holdings a good stock to buy?
A solid business, but the price is high. 5 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Medpace Holdings AI analysis
What does Medpace Holdings do?
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It is in Medical - Diagnostics & Research, based in Cincinnati, OH, United States, with 6,300 employees.
Does Medpace Holdings pay a dividend?
No. Medpace Holdings does not pay a dividend at the moment; in 2025 it returned $917 million to shareholders by buying back its own shares.
Is Medpace Holdings stock halal?
Yes. Medpace Holdings passes our halal screen: its business is permitted and its debt is 0.6% of its market value, under the 30% limit. How we check
How has Medpace Holdings stock done over the past year?
Up 10.6% over the past twelve months, to $653.94. It traded between $393.42 and $692.68 and is 5.6% below its high.
Who are Medpace Holdings's competitors?
The largest listed companies in the same industry are Illumina, Labcorp Holdings, Quest Diagnostics and Guardant Health. The peers table on this page compares their profit, growth and price with Medpace Holdings's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.